Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studies
Sign Up to like & getrecommendations! Published in 2017 at "Current Medical Research and Opinion"
DOI: 10.1080/03007995.2017.1297701
Abstract: Abstract Objectives: This meta-analysis compared safety profiles (selected drug-related treatment-emergent adverse events [TEAEs]) of first-line pemetrexed plus carboplatin (PCb) area under the concentration-time curve 5 mg/min•mL (PCb5) or 6 mg/min•mL (PCb6), two widely used regimens in clinical… read more here.
Keywords: pcb6; first line; analysis; safety ... See more keywords
First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma
Sign Up to like & getrecommendations! Published in 2017 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2017.1340157
Abstract: ABSTRACT Background: Mesothelioma of peritoneal origin has wider variation in treatment outcomes than mesothelioma of pleural origin, likely because peritoneal mesothelioma comprises borderline malignant variants and aggressive malignant peritoneal mesothelioma (MPeM). This study retrospectively evaluates… read more here.
Keywords: chemotherapy; mesothelioma; first line; peritoneal mesothelioma ... See more keywords
Effect of renin-angiotensin system inhibitors on pemetrexed plus platinum-induced hematological toxicities: a multicenter retrospective study using three propensity score analyses.
Sign Up to like & getrecommendations! Published in 2021 at "Die Pharmazie"
DOI: 10.1691/ph.2021.1409
Abstract: Hematological toxicities induced by pemetrexed plus platinum therapy remain a critical issue in clinical practice. We hypothesized that inhibition of the renin-angiotensin system (RAS) can ameliorate pemetrexed-induced hematological toxicities through drug-drug interactions involving organic anion… read more here.
Keywords: hematological toxicities; renin angiotensin; plus platinum; pemetrexed plus ... See more keywords
Comparing the cost-effectiveness of sintilimab + pemetrexed plus platinum and pemetrexed plus platinum alone as a first-line therapy for Chinese patients with nonsquamous non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2023 at "Translational Cancer Research"
DOI: 10.21037/tcr-22-2030
Abstract: Background Pemetrexed plus platinum alone is the conventional first-line therapy for locally advanced metastatic nonsquamous non-small cell lung cancer (NSCLC) without targetable genetic aberrations. The ORIENT-11 trial revealed that sintilimab + pemetrexed plus platinum could… read more here.
Keywords: plus platinum; patients nonsquamous; cost; first line ... See more keywords